NF-κB与胃癌的靶向治疗研究进展  

NF-κB and targeted therapy of gastric cancer:recent research progress

作　　者：刘静[1] 刘冰熔[1] 刘婷[1] 

机构地区：[1]哈尔滨医科大学附属二院消化内科,黑龙江省哈尔滨市150086

出　　处：《世界华人消化杂志》2012年第3期181-186,共6页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.30871152

摘　　要：胃癌是世界上导致癌症相关死亡的主要原因之一.虽然普遍认为幽门螺杆菌感染是导致胃癌发生的重要原因,但胃癌发生的确切机制尚未被阐明.癌症的发生、发展主要与细胞生存和死亡信号的平衡相关,致癌物质和炎症因子能活化大多数细胞的生存信号,从本质上促成肿瘤的形成.核转录因子-kappaB(NF-κB)是细胞主要的生存信号之一,近年来在一些细胞学和动物模型实验中均发现NF-κB的活化与胃癌发生和化疗抵抗等过程密切相关,抑制NF-κB的活化可提高胃癌细胞对化疗药物的敏感性.本文对NF-κB转录途径在胃癌演进中的机制以及其靶向治疗的相关进展综述如下.Gastric cancer is a main cause of cancer death worldwide.Despite the knowledge that Helicobacter pylori constitutes the main cause of gastric cancer,the mechanisms for gastric carcinogenesis are still elucidated.Cancer development and progression depend on the balance between cell survival and death signals.Common cell survival signaling pathways are activated by carcinogens as well as by inflammatory cytokines,which contribute substantially to tumorigenesis.Nuclear factor-kappaB （NF-κB） is a major cell survival signal.Recent studies with cell culture systems and animal models have certified the links between NF-κB and gastric carcinogenesis and resistance to chemotherapy.Inhibition of NF-κB activation can enhance the sensitivity of cancer cells to chemotherapeutic drugs.In this review,we summarize recent progress in understanding the role of the NF-κB pathway in gastric cancer development as well as in modulating NF-κB for gastric cancer prevention and therapy.

关 键 词：胃癌 核转录因子-kappaB 靶向治疗 

分 类 号：R735.2[医药卫生—肿瘤]